NRIX / Q3 FY2026

Nurix Therapeutics

Reports 2026-10-09 (tentative) · Time unconfirmed

Published forecast

Oct 5, 2026, 12:32 AM PDT

Opus 5.5 High in Shortcut

Shortcut EPS

5.30

EPS basis comparison pending

Street EPS

5.11

Frozen October 4 snapshot

Actual EPS

—

Awaiting earnings

Conditional forecast: assumes the full $700 million Roche license payment is recognized this quarter. Percentage comparison and win/loss scoring await a matched earnings definition.

Explore the model.

Open the assumptions and calculations behind this earnings forecast.

Open in Shortcut ↗Download XLSX ↓

Behind the estimate.

The forecast treats Roche’s $700 million upfront license as revenue this quarter, drawing on earlier license deals as precedent. Collaboration payments add $15.2 million, while Roche’s share of development costs reduces expenses. That produces the selected $5.30 EPS case.

Recognition timing drives the result. The model’s alternative, which spreads the license payment over time, is a $0.51 loss per share. The selected case also assumes a 1.6% tax rate and no normalization adjustments. Those assumptions are disclosed in the workbook, and the Street comparison remains unscored until the definitions match.

Forecast and independent review: Opus 5.5 High in Shortcut.

On the record.

Reporting period: Q3 FY2026, ended 2026-08-31
Reporting basis: Normalized diluted EPS, USD per common share; zero adjustments assumed, consensus basis unverified
Published: Oct 5, 2026, 12:32 AM PDT
Model / effort: Opus 5.5 · High effort

Original forecasts, models and publication times remain on the record.